Gregory Divis - Avadel Pharmaceuticals Executive Vice President Chief Commercial Officer
| AVDL Stock | USD 11.15 0.11 0.98% |
President
Mr. Gregory J. Divis, serves as Chief Executive Officer, Chief Operating Officer, Executive Vice President, Director of the Company. Mr. Divis brings to this role more than 25 years of experience in the pharmaceutical industry, and is responsible for managing commercial strategy and execution across all of the Companys portfolio products. Prior to joining Avadel, Mr. Divis served as an Operating Partner for Linden Capital, a middlemarket healthcarefocused private equity firm from June 2015 to December 2016. Prior to Linden Capital, from June 2010 to November 2014 Mr. Divis was the President and Chief Executive Officer of KV Pharmaceutical Company, a company engaged in the development of proprietary drug delivery systems and formulation technologies. On August 4, 2012, KV and certain of its subsidiaries filed voluntary petitions for reorganization under Chapter 11 of the United States Bankruptcy Code and, on September 16, 2013, successfully emerged pursuant to a plan of reorganization. Following bankruptcy, KV changed its name to Lumara Health, Inc., strengthened its business and engaged in a series of transactions culminating in its acquisition by AMAG Pharmaceuticals in November 2014. Mr. Divis has also held such notable roles as President, TherRx Corporationrationration, VicePresident, Business Development Lifecycle Management at SanofiAventis and VicePresident and General Manager, UK and Ireland, for ScheringPlough Corporationrationration. Mr. Divis is a graduate of the University of Iowa. since 2019.
| Age | 58 |
| Tenure | 6 years |
| Address | 10 Earlsfort Terrace, Dublin, Ireland, D02 T380 |
| Phone | 353 1 901 5201 |
| Web | https://www.avadel.com |
Gregory Divis Latest Insider Activity
Tracking and analyzing the buying and selling activities of Gregory Divis against Avadel Pharmaceuticals stock is an integral part of due diligence when investing in Avadel Pharmaceuticals. Gregory Divis insider activity provides valuable insight into whether Avadel Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Avadel Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Avadel Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Gregory Divis over a month ago Acquisition by Gregory Divis of 9598 shares of Avadel Pharmaceuticals at 9.977 subject to Rule 16b-3 | ||
Gregory Divis over three months ago Acquisition by Gregory Divis of 52000 shares of Avadel Pharmaceuticals subject to Rule 16b-3 | ||
Gregory Divis over six months ago Acquisition by Gregory Divis of 402 shares of Avadel Pharmaceuticals at 9.82 subject to Rule 16b-3 |
Avadel Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0721) % which means that it has lost $0.0721 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3465) %, meaning that it created substantial loss on money invested by shareholders. Avadel Pharmaceuticals' management efficiency ratios could be used to measure how well Avadel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.35. The value of Return On Capital Employed is expected to slide to -0.39. At this time, Avadel Pharmaceuticals' Non Current Assets Total are quite stable compared to the past year. Intangibles To Total Assets is expected to rise to 0.20 this year, although the value of Non Currrent Assets Other will most likely fall to about 7.2 M.Similar Executives
| Found 11 records | PRESIDENT Age | ||
| Sandeep Raktate | Amneal Pharmaceuticals, Class | N/A | |
| Daniel Barber | Aquestive Therapeutics | 49 | |
| Sanjay Jain | Amneal Pharmaceuticals, Class | N/A | |
| Anastasios Konidaris | Amneal Pharmaceuticals, Class | 58 | |
| Nikita Shah | Amneal Pharmaceuticals, Class | 47 | |
| Andrew Boyer | Amneal Pharmaceuticals, Class | 59 | |
| Joseph Todisco | Amneal Pharmaceuticals, Class | 45 | |
| Peter Boyd | Aquestive Therapeutics | 59 | |
| Rafael Andino | Clearside Biomedical | 60 | |
| Stephen Manzano | Amneal Pharmaceuticals, Class | 55 | |
| Joseph Greer | Amneal Pharmaceuticals, Class | N/A | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0721 |
Avadel Pharmaceuticals Leadership Team
Elected by the shareholders, the Avadel Pharmaceuticals' board of directors comprises two types of representatives: Avadel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Avadel. The board's role is to monitor Avadel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Avadel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Avadel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Kim, Chief Officer | ||
| Susan Rodriguez, Chief Officer | ||
| Christian PharmD, Chief Affairs | ||
| Gregory Davis, VP Development | ||
| Jason Vaughn, Senior Operations | ||
| Gregory Divis, Executive Vice President Chief Commercial Officer | ||
| Jennifer PharmD, Senior Affairs | ||
| Mark Elrod, Vice Sales | ||
| Jordan MD, Consultant | ||
| Angie Woods, Vice Culture | ||
| Thomas McHugh, Principal VP | ||
| Steven Sullivan, VP Operations | ||
| Jerad Seurer, General Secretary |
Avadel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Avadel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0721 | ||||
| Profit Margin | (0.14) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 1.03 B | ||||
| Shares Outstanding | 96.9 M | ||||
| Shares Owned By Insiders | 4.89 % | ||||
| Shares Owned By Institutions | 84.85 % | ||||
| Number Of Shares Shorted | 12.31 M | ||||
| Price To Earning | 61.46 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Revenue Per Share | Quarterly Revenue Growth 0.932 | Return On Assets | Return On Equity |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.